
	Ziprasidone in mania: short- and long-term data Authors: Keck PE, et al. Title: Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Reference: APA 2004 New Research Presentation. Purpose: To evaluate the efficacy and tolerability of ziprasidone in the treatment of bipolar mania. Study design: Open-label extension of a 3-week, double-blinded, placebo-controlled trial. Follow up: 52 weeks. Patients: 127 patients. Treatment: Ziprasidone 40–160 mg/day. Results: Continued improvement (from the double-blinded phase) of ziprasidone-treated patients was observed in terms of MRS and CGI scores. Ziprasidone was well tolerated, with the most frequent side effects being somnolence (36%), insomnia (32%), headache (28%), anxiety (21%) and depression (20%). The incidence of weight gain was low.